Yongxiang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yongxiang Wang has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Yifeng Du
Shandong Provincial Hospital Affiliated to Shandong First Medical University
32 shared publications Lin Cong
Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education, Department of Neurology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, PR China
22 shared publicationsXiaolei Han
Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education, Department of Neurology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, PR China
19 shared publicationsYi Dong
Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education, Department of Neurology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, PR China
19 shared publications- Chengxuan Qiu
Aging Research Center, Department of Neurobiology, Care Sciences and Society Karolinska Institutet and Stockholm University Stockholm Sweden
18 shared publications Ming Mao
Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education, Department of Neurology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, PR China
16 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Springer Nature in Communications Medicine
Associations of plasma neuron-derived extracellular vesicles with MRI-derived parasagittal dura metrics across the cognitive continuum
Background: Neuron-derived extracellular vesicles (NDEVs) have been implicated in cognitive phenotypes; however, whether their physical properties are associated with cognition and with MRI-derived markers of brain fluid clearance pathways remains unclear. We aimed to characterize plasma NDEV properties across the cognitive continuum and to examine their associations with these imaging markers. Methods: This population-based study included 156 rural-dwelling older adults (aged ≥60 years; 62.8% women) from the MIND-China study. Plasma NDEV concentration and diameter were quantified using the ExoView platform. MRI-derived parasagittal dural (PSD) and cervical lymph node (LN) metrics, including structural measures and signal intensity, were assessed on three-dimensional T2 fluid-attenuated inversion recovery magnetic resonance imaging. Associations were examined using group comparisons and regression models. Results: Here we show that, among the 156 participants, 37 had mild cognitive impairment and 13 had clinically diagnosed Alzheimer’s disease (AD). Larger plasma NDEVs were associated with AD and poorer cognitive function, whereas NDEV concentration was not significantly associated with AD. Greater MRI-derived PSD metrics were associated with lower plasma NDEV concentration, but not with total extracellular vesicle concentration. Conclusions: Plasma NDEV size is associated with AD and poorer cognition, and MRI-derived PSD metrics are associated with plasma NDEV profiles. These findings warrant further evaluation of plasma NDEV properties as candidate biomarkers, including assessments of diagnostic accuracy and disease specificity in larger longitudinal cohorts.
- 21 September 2026
- Published by Springer Nature in Communications Medicine
Open AccessAssociations of plasma neuron-derived extracellular vesicles with MRI-derived parasagittal dura metrics across the cognitive continuum
Background: Neuron-derived extracellular vesicles (NDEVs) have been implicated in cognitive phenotypes; however, whether their physical properties are associated with cognition and with MRI-derived markers of brain fluid clearance pathways remains unclear. We aimed to characterize plasma NDEV properties across the cognitive continuum and to examine their associations with these imaging markers. Methods: This population-based study included 156 rural-dwelling older adults (aged ≥60 years; 62.8% women) from the MIND-China study. Plasma NDEV concentration and diameter were quantified using the ExoView platform. MRI-derived parasagittal dural (PSD) and cervical lymph node (LN) metrics, including structural measures and signal intensity, were assessed on three-dimensional T2 fluid-attenuated inversion recovery magnetic resonance imaging. Associations were examined using group comparisons and regression models. Results: Here we show that, among the 156 participants, 37 had mild cognitive impairment and 13 had clinically diagnosed Alzheimer’s disease (AD). Larger plasma NDEVs were associated with AD and poorer cognitive function, whereas NDEV concentration was not significantly associated with AD. Greater MRI-derived PSD metrics were associated with lower plasma NDEV concentration, but not with total extracellular vesicle concentration. Conclusions: Plasma NDEV size is associated with AD and poorer cognition, and MRI-derived PSD metrics are associated with plasma NDEV profiles. These findings warrant further evaluation of plasma NDEV properties as candidate biomarkers, including assessments of diagnostic accuracy and disease specificity in larger longitudinal cohorts.
- 22 July 2026
- Published by Wiley in Journal of Internal Medicine
- Vol. 300 (5) , 623-641
Fecal microbiota transplantation‐based treatment protocol for chronic insomnia disorder: A randomized, double‐blind, placebo‐controlled trial
Objective: Chronic insomnia disorder is common and burdensome, and current treatments remain limited. We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial to determine whether a fecal microbiota transplantation (FMT)‐based treatment protocol improves sleep outcomes in adults with chronic insomnia disorder. Methods: Participants were randomly assigned 1:1 to receive short‐course antibiotic pretreatment followed by donor microbiota capsules ( n = 40) or placebo capsules without antibiotic pretreatment ( n = 40). Within each group, participants were further randomized to receive synbiotic supplementation or matched placebo for prespecified exploratory subgroup analyses. The primary outcome was polysomnography‐measured sleep efficiency (SE) at 1 month after treatment. Secondary outcomes included other polysomnographic parameters, patient‐reported sleep outcomes, and safety; microbiota analyses were exploratory. Results: Compared with placebo, the FMT‐based treatment protocol improved SE (adjusted between‐group difference, 13.9 percentage points; 95% CI 7.29–20.41; p = 0.003) and reduced wake after sleep onset. Synbiotic assignment did not suggest meaningful differences in SE. Insomnia Severity Index and Pittsburgh Sleep Quality Index scores showed sustained improvement from 2 to 6 months. Treatment was well tolerated, with mild, self‐limited adverse events and no serious adverse events. The intervention increased microbial richness and diversity and altered community structure; responders and non‐responders showed similar posttreatment β ‐diversity change but differed in baseline microbiota composition. Conclusion: In adults with chronic insomnia disorder, an FMT‐based treatment protocol incorporating antibiotic pretreatment improved objective sleep continuity and sustained subjective insomnia outcomes. Baseline microbial composition may contribute to treatment heterogeneity and merits further investigation.
- 22 July 2026
- Published by Wiley in Journal of Internal Medicine
- Vol. 300 (5) , 623-641
Fecal microbiota transplantation‐based treatment protocol for chronic insomnia disorder: A randomized, double‐blind, placebo‐controlled trial
Objective: Chronic insomnia disorder is common and burdensome, and current treatments remain limited. We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial to determine whether a fecal microbiota transplantation (FMT)‐based treatment protocol improves sleep outcomes in adults with chronic insomnia disorder. Methods: Participants were randomly assigned 1:1 to receive short‐course antibiotic pretreatment followed by donor microbiota capsules ( n = 40) or placebo capsules without antibiotic pretreatment ( n = 40). Within each group, participants were further randomized to receive synbiotic supplementation or matched placebo for prespecified exploratory subgroup analyses. The primary outcome was polysomnography‐measured sleep efficiency (SE) at 1 month after treatment. Secondary outcomes included other polysomnographic parameters, patient‐reported sleep outcomes, and safety; microbiota analyses were exploratory. Results: Compared with placebo, the FMT‐based treatment protocol improved SE (adjusted between‐group difference, 13.9 percentage points; 95% CI 7.29–20.41; p = 0.003) and reduced wake after sleep onset. Synbiotic assignment did not suggest meaningful differences in SE. Insomnia Severity Index and Pittsburgh Sleep Quality Index scores showed sustained improvement from 2 to 6 months. Treatment was well tolerated, with mild, self‐limited adverse events and no serious adverse events. The intervention increased microbial richness and diversity and altered community structure; responders and non‐responders showed similar posttreatment β ‐diversity change but differed in baseline microbiota composition. Conclusion: In adults with chronic insomnia disorder, an FMT‐based treatment protocol incorporating antibiotic pretreatment improved objective sleep continuity and sustained subjective insomnia outcomes. Baseline microbial composition may contribute to treatment heterogeneity and merits further investigation.
- Open Access
- 9 July 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (12) , 6762-6773
The choroid plexus, cognitive decline, and incident dementia: insights from the UK Biobank
The choroid plexus (CP) plays a crucial role in cerebrospinal fluid secretion and the maintenance of brain homeostasis. Its structure and function have been implicated in the pathogenesis of dementia; however, the longitudinal associations of CP with dementia and structural brain biomarkers remain unclear. This prospective cohort study utilized data from the UK Biobank, including 45,306 participants (mean age, 64 years; 47.2% men) who underwent 3.0 T multiparametric brain MRI scans. CP volume and signal intensity were quantified by FreeSurfer software. Measures of grey or white matter macrostructures or microstructures were derived from structural or diffusion MRI. Dementia outcomes were identified using linkage of hospital admission records or death register. Tests for global and domain-specific cognitive functions were administrated at baseline and follow up. Data were analyzed using Cox proportional hazards, Mendelian randomization, linear mixed-effects models, and mediation models. Advancing age was correlated with increased CP volume (R = 0.49, P < 0.001) and decreased CP signal intensity (R = −0.44, P < 0.001). Meanwhile, greater CP volume was associated with an increased risk of all-cause dementia (hazard ratio, 1.61; 95% confidence interval, 1.32–1.97), while higher CP intensity was correlated with a reduced dementia risk (0.44; 0.36–0.55). Reduced volumes of the hippocampus, amygdala, and nucleus accumbens, increased white matter hyperintensity volume, mean diffusivity, and isotropic compartment volume fraction, and decreased intracellular volume fraction significantly mediated up to 42.9% of these associations. This study provides evidence supporting a causal relationship between CP morphological parameters and dementia risk that is partly mediated by specific brain phenotypes, and further suggests that the CP parameters may be valuable biomarkers for structural brain aging and dementia.
- 9 July 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (12) , 6762-6773
Open AccessThe choroid plexus, cognitive decline, and incident dementia: insights from the UK Biobank
The choroid plexus (CP) plays a crucial role in cerebrospinal fluid secretion and the maintenance of brain homeostasis. Its structure and function have been implicated in the pathogenesis of dementia; however, the longitudinal associations of CP with dementia and structural brain biomarkers remain unclear. This prospective cohort study utilized data from the UK Biobank, including 45,306 participants (mean age, 64 years; 47.2% men) who underwent 3.0 T multiparametric brain MRI scans. CP volume and signal intensity were quantified by FreeSurfer software. Measures of grey or white matter macrostructures or microstructures were derived from structural or diffusion MRI. Dementia outcomes were identified using linkage of hospital admission records or death register. Tests for global and domain-specific cognitive functions were administrated at baseline and follow up. Data were analyzed using Cox proportional hazards, Mendelian randomization, linear mixed-effects models, and mediation models. Advancing age was correlated with increased CP volume (R = 0.49, P < 0.001) and decreased CP signal intensity (R = −0.44, P < 0.001). Meanwhile, greater CP volume was associated with an increased risk of all-cause dementia (hazard ratio, 1.61; 95% confidence interval, 1.32–1.97), while higher CP intensity was correlated with a reduced dementia risk (0.44; 0.36–0.55). Reduced volumes of the hippocampus, amygdala, and nucleus accumbens, increased white matter hyperintensity volume, mean diffusivity, and isotropic compartment volume fraction, and decreased intracellular volume fraction significantly mediated up to 42.9% of these associations. This study provides evidence supporting a causal relationship between CP morphological parameters and dementia risk that is partly mediated by specific brain phenotypes, and further suggests that the CP parameters may be valuable biomarkers for structural brain aging and dementia.
- Open Access
- 1 July 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (7) , e71647
Multimorbidity burden and patterns associated with DeepBrainNet‐derived brain–age gap in dementia‐free older adults: A community‐based study
INTRODUCTION: Emerging evidence has linked chronic diseases with structural brain measures; however, the relationship between multimorbidity patterns and brain–age gap is unclear. METHODS: This community‐based study involved 1151 dementia‐free older adults in Multimodal Interventions to Delay Dementia and Disability in Rural China (MIND‐China). Multimorbidity was defined as coexistence of two or more chronic diseases. Hierarchical cluster analysis was used to identify five patterns of multimorbidity. We additionally defined cardiometabolic multimorbidity as coexistence of two or more cardiometabolic diseases. The predicted brain age was estimated using DeepBrainNet. Data were analyzed using linear regression models. RESULTS: The number of chronic diseases, multimorbidity, and cardiometabolic multimorbidity were significantly associated with larger brain–age gap ( p < 0.05). The multimorbidity clusters comprising cerebrovascular disease and metabolic disorders or biliary tract diseases, dorsopathies, anemia, and hearing problems were significantly correlated with larger brain–age gap ( p < 0.05). DISCUSSION: The overall burden and cardiometabolic pattern of multimorbidity are associated with advanced brain aging in dementia‐free older adults.
- 1 July 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (7) , e71647
Open AccessMultimorbidity burden and patterns associated with DeepBrainNet‐derived brain–age gap in dementia‐free older adults: A community‐based study
INTRODUCTION: Emerging evidence has linked chronic diseases with structural brain measures; however, the relationship between multimorbidity patterns and brain–age gap is unclear. METHODS: This community‐based study involved 1151 dementia‐free older adults in Multimodal Interventions to Delay Dementia and Disability in Rural China (MIND‐China). Multimorbidity was defined as coexistence of two or more chronic diseases. Hierarchical cluster analysis was used to identify five patterns of multimorbidity. We additionally defined cardiometabolic multimorbidity as coexistence of two or more cardiometabolic diseases. The predicted brain age was estimated using DeepBrainNet. Data were analyzed using linear regression models. RESULTS: The number of chronic diseases, multimorbidity, and cardiometabolic multimorbidity were significantly associated with larger brain–age gap ( p < 0.05). The multimorbidity clusters comprising cerebrovascular disease and metabolic disorders or biliary tract diseases, dorsopathies, anemia, and hearing problems were significantly correlated with larger brain–age gap ( p < 0.05). DISCUSSION: The overall burden and cardiometabolic pattern of multimorbidity are associated with advanced brain aging in dementia‐free older adults.
- Open Access
- 10 May 2026
- Published by Elsevier in SSRN Electronic Journal
The Longitudinal Association of Multimorbidity with Frailty in Middle-Aged and Older Adults: A Prospective Cohort Study in the UK Biobank
Background: The relationship between multimorbidity and the frailty syndrome remains poorly characterized. We aimed to investigate the longitudinal association of multimorbidity with the frailty syndrome assessed using both the Rockwood frailty index (FI) and the Fried frailty phenotype among middle-aged and older adults in the United Kingdom.Methods: This prospective cohort study used data from the UK Biobank. At baseline, multimorbidity was defined as ≥2 long-term conditions (LTCs) and was evaluated based on the LTCs counts and clusters. At both baseline and follow-ups, we used five criteria (weight loss, exhaustion, slow walking speed, low hand-grip strength, and low physical activity) to define the Fried frailty phenotype (meeting three or more of the five indicators). The Rockwood FI was calculated using 49 variables representing a variety of physiological and mental health domains, symptoms, disabilities, and diagnosed diseases, and the Rockwood FI-defined frailty was referred to as FI ≥0·25. Data were analyzed using Cox proportional hazards models.Findings: Among the 29 595 baseline frailty-free participants defined using the Rockwood FI methods, 1505 (5·1%) developed incident frailty over a median follow-up of 9·40 years. Among the 67 213 baseline frailty-free participants defined using the Fried frailty phenotype, 1467 (2·2%) developed incident Fried frailty phenotype over a median follow-up of 9·62 years. Multimorbidity at baseline was significantly associated with elevated risks of the frailty syndrome (the Rockwood FI: hazard ratio [HR] = 3·51, 95% confidence interval [CI] = 3·04-4·04, p<0·001; the Fried frailty phenotype: HR = 2·19, 95% CI = 1·95-2·46, p<0·001). The risk of developing the frailty syndrome increased linearly with a greater number of LTCs. The multimorbidity clusters that were significantly associated with the Rockwood FI-defined frailty included cardiometabolic (HR = 1·88, 95% CI = 1·66-2·14), respiratory-immune (1·66, 1·49-1·85), cancer-endocrine (1·44, 1·26-1·64), and mixed (2·15, 1·94-2·40) clusters; for the Fried frailty phenotype, cardiometabolic (1·64, 1·45-1·85), neurological (1·47, 1·06-2·05), inflammatory bowel disease (2·84, 1·91-4·22), and mixed (1·98, 1·77-2·22) clusters.Interpretation: Multimorbidity is strongly associated with an increased risk of the frailty syndrome in middle-aged and older adults, with the association being specific for certain disease clusters. Managing multimorbidity from midlife onward may be crucial to delaying the frailty syndrome.
- 10 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe Longitudinal Association of Multimorbidity with Frailty in Middle-Aged and Older Adults: A Prospective Cohort Study in the UK Biobank
Background: The relationship between multimorbidity and the frailty syndrome remains poorly characterized. We aimed to investigate the longitudinal association of multimorbidity with the frailty syndrome assessed using both the Rockwood frailty index (FI) and the Fried frailty phenotype among middle-aged and older adults in the United Kingdom.Methods: This prospective cohort study used data from the UK Biobank. At baseline, multimorbidity was defined as ≥2 long-term conditions (LTCs) and was evaluated based on the LTCs counts and clusters. At both baseline and follow-ups, we used five criteria (weight loss, exhaustion, slow walking speed, low hand-grip strength, and low physical activity) to define the Fried frailty phenotype (meeting three or more of the five indicators). The Rockwood FI was calculated using 49 variables representing a variety of physiological and mental health domains, symptoms, disabilities, and diagnosed diseases, and the Rockwood FI-defined frailty was referred to as FI ≥0·25. Data were analyzed using Cox proportional hazards models.Findings: Among the 29 595 baseline frailty-free participants defined using the Rockwood FI methods, 1505 (5·1%) developed incident frailty over a median follow-up of 9·40 years. Among the 67 213 baseline frailty-free participants defined using the Fried frailty phenotype, 1467 (2·2%) developed incident Fried frailty phenotype over a median follow-up of 9·62 years. Multimorbidity at baseline was significantly associated with elevated risks of the frailty syndrome (the Rockwood FI: hazard ratio [HR] = 3·51, 95% confidence interval [CI] = 3·04-4·04, p<0·001; the Fried frailty phenotype: HR = 2·19, 95% CI = 1·95-2·46, p<0·001). The risk of developing the frailty syndrome increased linearly with a greater number of LTCs. The multimorbidity clusters that were significantly associated with the Rockwood FI-defined frailty included cardiometabolic (HR = 1·88, 95% CI = 1·66-2·14), respiratory-immune (1·66, 1·49-1·85), cancer-endocrine (1·44, 1·26-1·64), and mixed (2·15, 1·94-2·40) clusters; for the Fried frailty phenotype, cardiometabolic (1·64, 1·45-1·85), neurological (1·47, 1·06-2·05), inflammatory bowel disease (2·84, 1·91-4·22), and mixed (1·98, 1·77-2·22) clusters.Interpretation: Multimorbidity is strongly associated with an increased risk of the frailty syndrome in middle-aged and older adults, with the association being specific for certain disease clusters. Managing multimorbidity from midlife onward may be crucial to delaying the frailty syndrome.
- 23 April 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (4) , 417-429
Autonomic modulation following fecal microbiota transplantation in chronic insomnia
To determine whether fecal microbiota transplantation (FMT) modulates autonomic function in chronic insomnia disorder and whether autonomic rebalancing mediates sleep improvement. This prespecified exploratory analysis was embedded within a multicenter, double-blind, randomized, placebo-controlled trial of FMT for chronic insomnia. The original trial was designed to evaluate the efficacy and safety of the FMT-based treatment protocol, with polysomnography-measured sleep efficiency at 1 month as the primary endpoint. Eighty adults were randomly assigned to receive either FMT (n = 40) or placebo capsules (n = 40). Overnight polysomnography was conducted at baseline and 1 month, and heart rate variability indices were derived to quantify autonomic regulation. Sleep outcomes included PSG-derived metrics and validated subjective questionnaires. Associations between changes in autonomic parameters and sleep outcomes were examined using correlation analyses. Mediation analysis was performed to evaluate whether autonomic changes statistically mediated FMT-associated improvements in sleep. Gut microbiota composition was profiled using 16S rRNA gene sequencing. In the original trial, the FMT-based treatment met its prespecified primary endpoint, with significantly improved polysomnography-measured sleep efficiency at 1 month. In this exploratory analysis, FMT significantly reduced the LF/HF ratio (-0.10; 95% CI, -0.18 to -0.02; p = 0.010). A reduction in LF/HF was associated with longer TST (β = -0.41; p = 0.004). Mediation analysis showed that LF/HF accounted for 49.7% of the FMT effect on TST (ACME = 19.44 min; p = 0.018). FMT induced microbial compositional remodeling associated with the nocturnal LF/HF ratio, including enrichment of Lachnospira eligens, Christensenellaceae R-7 group, Ruminococcaceae, and Coprococcus, and depletion of Prevotella copri, Streptococcus, and Faecalibacterium. These findings provide clinical exploratory evidence for autonomic system as a potential pathway through which microbiota-targeted interventions may alleviate insomnia. Further studies are needed to determine the durability and clinical significance of these findings. ClinicalTrials.gov: NCT05917379 (June 23, 2023).
- 23 April 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (4) , 417-429
Autonomic modulation following fecal microbiota transplantation in chronic insomnia
To determine whether fecal microbiota transplantation (FMT) modulates autonomic function in chronic insomnia disorder and whether autonomic rebalancing mediates sleep improvement. This prespecified exploratory analysis was embedded within a multicenter, double-blind, randomized, placebo-controlled trial of FMT for chronic insomnia. The original trial was designed to evaluate the efficacy and safety of the FMT-based treatment protocol, with polysomnography-measured sleep efficiency at 1 month as the primary endpoint. Eighty adults were randomly assigned to receive either FMT (n = 40) or placebo capsules (n = 40). Overnight polysomnography was conducted at baseline and 1 month, and heart rate variability indices were derived to quantify autonomic regulation. Sleep outcomes included PSG-derived metrics and validated subjective questionnaires. Associations between changes in autonomic parameters and sleep outcomes were examined using correlation analyses. Mediation analysis was performed to evaluate whether autonomic changes statistically mediated FMT-associated improvements in sleep. Gut microbiota composition was profiled using 16S rRNA gene sequencing. In the original trial, the FMT-based treatment met its prespecified primary endpoint, with significantly improved polysomnography-measured sleep efficiency at 1 month. In this exploratory analysis, FMT significantly reduced the LF/HF ratio (-0.10; 95% CI, -0.18 to -0.02; p = 0.010). A reduction in LF/HF was associated with longer TST (β = -0.41; p = 0.004). Mediation analysis showed that LF/HF accounted for 49.7% of the FMT effect on TST (ACME = 19.44 min; p = 0.018). FMT induced microbial compositional remodeling associated with the nocturnal LF/HF ratio, including enrichment of Lachnospira eligens, Christensenellaceae R-7 group, Ruminococcaceae, and Coprococcus, and depletion of Prevotella copri, Streptococcus, and Faecalibacterium. These findings provide clinical exploratory evidence for autonomic system as a potential pathway through which microbiota-targeted interventions may alleviate insomnia. Further studies are needed to determine the durability and clinical significance of these findings. ClinicalTrials.gov: NCT05917379 (June 23, 2023).
- 17 April 2026
- Published by Elsevier in Sleep Medicine Reviews
- Vol. 88, 102290
Polysomnography parameters in typically development and neuropsychiatric children: A systematic review and meta-analysis
- 17 April 2026
- Published by Elsevier in Sleep Medicine Reviews
- Vol. 88, 102290
Polysomnography parameters in typically development and neuropsychiatric children: A systematic review and meta-analysis
- 7 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (7) , e045747
Characterizing Intracranial Atherosclerotic Stenosis Associated With Cognitive Phenotypes Among Older Adults Who Are Dementia Free: A Population‐Based Study
Background: Evidence has linked intracranial atherosclerotic stenosis (ICAS) with cognitive impairment in patients with stroke. We characterized ICAS associated with cognitive phenotypes in the general older population. Methods: This study included 1031 participants without dementia from the community‐based MIND‐China (Multimodal Interventions to Delay Dementia and Disability in Rural China) magnetic resonance imaging substudy. The degree of stenosis was assessed using the Warfarin–Aspirin Symptomatic Intracranial Disease criteria. ICAS was defined as arterial stenosis ≥50%. The ICAS burden was assessed according to the number and severity of ICAS. Mild cognitive impairment (MCI) was defined following Petersen's criteria. Amnestic MCI was defined as MCI with the presence of memory impairment. Data were analyzed using multivariable logistic and linear regression models. Results: Of the 1031 participants, 240 (23.28%) had MCI. Higher ICAS burden was associated with increased likelihoods of MCI (odds ratio [OR], 1.89 [95% CI, 1.02–3.41]) and amnestic MCI (OR, 2.11 [95% CI, 1.13–3.92]), and reduced Z scores of global cognition (β, −0.21 [95% CI, −0.35 to −0.07]), memory (β, −0.40 [95% CI, −0.61 to −0.18]), and verbal fluency (β, −0.28 [95% CI, −0.47 to −0.08]). More severe ICAS was associated with lower memory Z score and a greater number of ICAS was associated with lower Z scores of global cognition, memory, and verbal fluency (all P Z scores of memory, verbal fluency, and attention (all P <0.05). Conclusions: The severity and location of ICAS are crucial for the associations of ICAS with MCI, amnestic MCI, and poor cognition in older adults. Cognitive assessments are warranted for older adults with ICAS.
- 7 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (7) , e045747
Characterizing Intracranial Atherosclerotic Stenosis Associated With Cognitive Phenotypes Among Older Adults Who Are Dementia Free: A Population‐Based Study
Background: Evidence has linked intracranial atherosclerotic stenosis (ICAS) with cognitive impairment in patients with stroke. We characterized ICAS associated with cognitive phenotypes in the general older population. Methods: This study included 1031 participants without dementia from the community‐based MIND‐China (Multimodal Interventions to Delay Dementia and Disability in Rural China) magnetic resonance imaging substudy. The degree of stenosis was assessed using the Warfarin–Aspirin Symptomatic Intracranial Disease criteria. ICAS was defined as arterial stenosis ≥50%. The ICAS burden was assessed according to the number and severity of ICAS. Mild cognitive impairment (MCI) was defined following Petersen's criteria. Amnestic MCI was defined as MCI with the presence of memory impairment. Data were analyzed using multivariable logistic and linear regression models. Results: Of the 1031 participants, 240 (23.28%) had MCI. Higher ICAS burden was associated with increased likelihoods of MCI (odds ratio [OR], 1.89 [95% CI, 1.02–3.41]) and amnestic MCI (OR, 2.11 [95% CI, 1.13–3.92]), and reduced Z scores of global cognition (β, −0.21 [95% CI, −0.35 to −0.07]), memory (β, −0.40 [95% CI, −0.61 to −0.18]), and verbal fluency (β, −0.28 [95% CI, −0.47 to −0.08]). More severe ICAS was associated with lower memory Z score and a greater number of ICAS was associated with lower Z scores of global cognition, memory, and verbal fluency (all P Z scores of memory, verbal fluency, and attention (all P <0.05). Conclusions: The severity and location of ICAS are crucial for the associations of ICAS with MCI, amnestic MCI, and poor cognition in older adults. Cognitive assessments are warranted for older adults with ICAS.
- 13 March 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (4) , 1939-1949
Lipid accumulation product index, serum inflammatory cytokines, and dementia in rural older adults: A population-based study
Background: The lipid accumulation product (LAP) index, a sex-specific indicator of abdominal lipid accumulation, has emerged as a predictor for cardiometabolic disease. However, its association with dementia has been rarely explored in population-based studies. Objective: We sought to investigate the associations of LAP index with all-cause dementia, Alzheimer's disease (AD), and vascular dementia (VaD) as well as with serum inflammatory cytokines among rural-dwelling older adults in China. Methods: This cross-sectional study included 5670 participants (age ≥ 60 years), with data available in 1851 individuals on serum inflammatory cytokines (interleukin-6, tumor necrosis factor-α, and monocyte chemoattractant protein-1). Dementia and subtypes were diagnosed following the international criteria. The LAP index was calculated as [waist circumference (cm)-65] × triglycerides (mmol/L) for men and [waist circumference (cm)-58] × triglycerides (mmol/L) for women. Data were analyzed using multiple logistic and linear regression models. Results: Of the 5670 participants, dementia was diagnosed in 305 persons (194 with AD and 100 with VaD). As a continuous variable, the LAP index was associated with multivariable-adjusted odds ratios of 1.28 (95% confidence interval: 1.01–1.61) for all-cause dementia, 1.40 (1.05–1.86) for AD, and 1.12 (0.75–1.66) for VaD. As a categorical variable, the highest (versus lowest) quintile of LAP index was associated with multivariable-adjusted odds ratios of 1.91 (1.17–3.12) for dementia, 2.18 (1.19–3.99) for AD, and 1.88 (0.78–4.53) for VaD. A higher LAP index was significantly correlated with serum inflammatory cytokines ( p < 0.05). Conclusions: High LAP index is linked with dementia and AD in older adults and chronic systemic inflammation might represent a plausible biological pathway.
- 13 March 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (4) , 1939-1949
Lipid accumulation product index, serum inflammatory cytokines, and dementia in rural older adults: A population-based study
Background: The lipid accumulation product (LAP) index, a sex-specific indicator of abdominal lipid accumulation, has emerged as a predictor for cardiometabolic disease. However, its association with dementia has been rarely explored in population-based studies. Objective: We sought to investigate the associations of LAP index with all-cause dementia, Alzheimer's disease (AD), and vascular dementia (VaD) as well as with serum inflammatory cytokines among rural-dwelling older adults in China. Methods: This cross-sectional study included 5670 participants (age ≥ 60 years), with data available in 1851 individuals on serum inflammatory cytokines (interleukin-6, tumor necrosis factor-α, and monocyte chemoattractant protein-1). Dementia and subtypes were diagnosed following the international criteria. The LAP index was calculated as [waist circumference (cm)-65] × triglycerides (mmol/L) for men and [waist circumference (cm)-58] × triglycerides (mmol/L) for women. Data were analyzed using multiple logistic and linear regression models. Results: Of the 5670 participants, dementia was diagnosed in 305 persons (194 with AD and 100 with VaD). As a continuous variable, the LAP index was associated with multivariable-adjusted odds ratios of 1.28 (95% confidence interval: 1.01–1.61) for all-cause dementia, 1.40 (1.05–1.86) for AD, and 1.12 (0.75–1.66) for VaD. As a categorical variable, the highest (versus lowest) quintile of LAP index was associated with multivariable-adjusted odds ratios of 1.91 (1.17–3.12) for dementia, 2.18 (1.19–3.99) for AD, and 1.88 (0.78–4.53) for VaD. A higher LAP index was significantly correlated with serum inflammatory cytokines ( p < 0.05). Conclusions: High LAP index is linked with dementia and AD in older adults and chronic systemic inflammation might represent a plausible biological pathway.
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e044196
Hypertension Mediates the Association of Triglyceride–Glucose–Body Mass Index With Vascular Brain Injury in Older Adults: A Population‐Based Magnetic Resonance Imaging Study
Background: Evidence has linked insulin resistance to hypertension, a major risk factor for vascular brain injury. We sought to explore the associations of the triglyceride–glucose–body mass index (TyG‐BMI), a surrogate marker of insulin resistance, with magnetic resonance imaging markers for vascular brain injury in older people and the role of hypertension in their associations. Methods: This population‐based study included 1268 participants (age ≥60 years; 58.60% women) from the MIND‐China (Multimodal Interventions to Delay Dementia and Disability in Rural China) magnetic resonance imaging substudy. White matter hyperintensities (WMHs), enlarged perivascular spaces, cerebral microbleeds (CMBs), and lacunes were assessed on structural brain magnetic resonance imaging scans following the Standards for Reporting Vascular Changes on Neuroimaging 1 criteria. The TyG‐BMI was calculated as ln(fasting triglyceride[mg/dL]×fasting glucose [mg/dL]/2)×BMI. Data were analyzed using the general linear, logistic, and mediation models controlling for multiple potential confounders. Results: A higher TyG‐BMI was significantly associated with greater volumes of total WMHs, periventricular WMHs, and deep WMHs (all P <0.05). After further adjustment for hypertension, the association remained statistically significant with deep WMH volume but was no longer significant with total and periventricular WMH volumes. The TyG‐BMI was not significantly associated with enlarged perivascular spaces, lacunes, or cerebral microbleeds. Mediation analysis indicated that hypertension significantly mediated around 26% to 49% of the associations between TyG‐BMI and WMH volumetric measures. The observed associations and mediation effects remained significant among participants free of diabetes or stroke. Conclusions: An increased insulin resistance, as indicated by high TyG‐BMI, is associated with greater WMH volumes in older adults, even among those free of diabetes or stroke, and their associations are largely mediated by hypertension.
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e044196
Hypertension Mediates the Association of Triglyceride–Glucose–Body Mass Index With Vascular Brain Injury in Older Adults: A Population‐Based Magnetic Resonance Imaging Study
Background: Evidence has linked insulin resistance to hypertension, a major risk factor for vascular brain injury. We sought to explore the associations of the triglyceride–glucose–body mass index (TyG‐BMI), a surrogate marker of insulin resistance, with magnetic resonance imaging markers for vascular brain injury in older people and the role of hypertension in their associations. Methods: This population‐based study included 1268 participants (age ≥60 years; 58.60% women) from the MIND‐China (Multimodal Interventions to Delay Dementia and Disability in Rural China) magnetic resonance imaging substudy. White matter hyperintensities (WMHs), enlarged perivascular spaces, cerebral microbleeds (CMBs), and lacunes were assessed on structural brain magnetic resonance imaging scans following the Standards for Reporting Vascular Changes on Neuroimaging 1 criteria. The TyG‐BMI was calculated as ln(fasting triglyceride[mg/dL]×fasting glucose [mg/dL]/2)×BMI. Data were analyzed using the general linear, logistic, and mediation models controlling for multiple potential confounders. Results: A higher TyG‐BMI was significantly associated with greater volumes of total WMHs, periventricular WMHs, and deep WMHs (all P <0.05). After further adjustment for hypertension, the association remained statistically significant with deep WMH volume but was no longer significant with total and periventricular WMH volumes. The TyG‐BMI was not significantly associated with enlarged perivascular spaces, lacunes, or cerebral microbleeds. Mediation analysis indicated that hypertension significantly mediated around 26% to 49% of the associations between TyG‐BMI and WMH volumetric measures. The observed associations and mediation effects remained significant among participants free of diabetes or stroke. Conclusions: An increased insulin resistance, as indicated by high TyG‐BMI, is associated with greater WMH volumes in older adults, even among those free of diabetes or stroke, and their associations are largely mediated by hypertension.